Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 8/20 | 0.46 |
| ▸ | NPC1 | O15118 | 7/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 6/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.46 |
| ▸ | RELA | Q04206 | 6/20 | 0.46 |
| ▸ | PKM | P14618 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5965259 | 1.00 | FGFR1 (0.50) | FGFR1SRCTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5901698 | 1.00 | FGFR1 (0.50) | FGFR1SRCTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8054624 | 0.87 | ALDH1A1 (0.51) | FGFR1SRCTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3960135 | 0.80 | PDE10A (0.51) | FGFR1SRCTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3960133 | 0.80 | PDE10A (0.51) | FGFR1SRCTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5901373 | 0.80 | PDE10A (0.51) | FGFR1SRCTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2140172 | 0.79 | CYP3A4 (0.56) | SMN1; SMN2ALDH1A1CYP3A4KDM4ERAB9A | |
| SCHEMBL6287497 | 0.78 | HTT (0.43) | FGFR1SRCTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL17929603 | 0.76 | APP (0.64) | GAAGLA | |
| SCHEMBL17929600 | 0.76 | APP (0.64) | MEN1KMT2AMAPTGAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339701-B1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-6849632-B2 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ZABLOCKI JEFF (US) | 2004-09-30 | — | — | US | disclosed |
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2003-11-20 | — | — | US | disclosed |
| EP-1339701-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6573264-B1 | Protecting skeletal muscles against damage, treating shock conditions, preserving donor tissue and organs used in transplants, treating cardiovascular diseases | CV THERAPEUTICS, INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2002064576-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CPT1B, CPT1A, ALOX15 | FGFR1 1306/4885SRC 3606/4885TDP1 3372/4885 |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | FGFR1 2522/4885SRC 4080/4885TDP1 3584/4885 |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | FGFR1 2522/4885SRC 4080/4885TDP1 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.